Vpr Overcomes Macrophage-Specific Restriction of HIV-1 Env Expression and Virion Production  by Mashiba, Michael et al.
Cell Host & Microbe
ArticleVpr Overcomes Macrophage-Specific Restriction
of HIV-1 Env Expression and Virion Production
Michael Mashiba,1,2,5 David R. Collins,3,5 Valeri H. Terry,4 and Kathleen L. Collins1,3,4,*
1Graduate Program in Immunology
2Medical Scientist Training Program
3Department of Microbiology and Immunology
4Department of Internal Medicine
University of Michigan, Ann Arbor, MI 48109, USA
5Co-first author
*Correspondence: klcollin@umich.edu
http://dx.doi.org/10.1016/j.chom.2014.10.014SUMMARY
The HIV-1 accessory protein Vpr enhances infection
of primary macrophages through unknown mecha-
nisms. Recent studies demonstrated that Vpr in-
teractions with the cellular DCAF1-DDB1-CUL4 E3
ubiquitin ligase complex limit activation of innate im-
munity and interferon (IFN) induction. We describe
a restriction mechanism that targets the HIV-1 en-
velope protein Env, but is overcome by Vpr and its
interaction with DCAF1. This restriction is active
in the absence of Vpr in HIV-1-infected primary mac-
rophages and macrophage-epithelial cell hetero-
karyons, but not epithelial cell lines. HIV-1-infected
macrophages lacking Vpr express more IFN
following infection, target Env for lysosomal degra-
dation, and produce fewer Env-containing virions.
Conversely, Vpr expression reduces IFN induction,
rescues Env expression, and enhances virion
release. Addition of IFN or silencing DCAF1 reduces
the amount of cell-associated Env and virion pro-
duction in wild-type HIV-1-infected primary macro-
phages. These findings provide insight into an IFN-
stimulated macrophage-specific restriction pathway
targeting HIV-1 Env that is counteracted by Vpr.
INTRODUCTION
To establish a persistent infection, lentiviruses encode acces-
sory proteins that are not required for replication in some cell
lines, but are necessary for infection in vivo (Malim and Emer-
man, 2008). Many of these accessory factors have been shown
to counteract host restriction factors that can limit HIV-1 infec-
tion (Collins and Collins, 2014). Interestingly, transformed cell
and primary cell systems vary in the extent to which they express
restriction factors targeted by these accessory proteins. For
example, primary monocytic cells harbor a postentry block to
HIV-1 infection that can be overcome by the simian immunode-
ficiency virus (SIV) accessory protein Vpx (Berger et al., 2011;
Sharova et al., 2008). Vpx binds a substrate adaptor of a cellular722 Cell Host & Microbe 16, 722–735, December 10, 2014 ª2014 Elsubiquitin ligase complex (damaged DNA binding protein 1-cullin
4-associated factor 1 [DCAF1]) to promote ubiquitylation and
proteasomal degradation of cellular restriction factors SAMHD1
(Laguette et al., 2011) and apolipoprotein B-editing complex 3A
(APOBEC3A) (Berger et al., 2011). In the absence of Vpx, these
restriction factors prevent productive infection of immature
monocytic cells.
Despite its importance for infection of immature monocytic
cells, no vpx gene has been found in any HIV-1 molecular clones
and as such, HIV-1 is not able to infect immature monocytic cells
that express high levels of SAMHD1 and APOBEC3A. However,
Vpr-expressing HIV-1 is able to efficiently infect monocyte-
derivedmacrophages (MDMs) that have lower levels of SAMHD1
and APOBEC3A (Ayinde et al., 2010). Like Vpx, Vpr utilizes
DCAF1 and the Rbx1/Cullin4A E3 ubiquitin ligase complex; how-
ever, some cellular targets of Vpr have only recently been iden-
tified, and their role in facilitating infection of restricted cell types
is not well understood. Elegant studies performed in transformed
cell-line systems demonstrated that Vpr activates the structure-
specific endonuclease (SSE) regulator SLX4 complex through an
interaction with DCAF1. Activation of SLX4 leads to evasion of
innate immune sensing of viral infection, possibly by enhanced
processing of HIV-1 DNA replication intermediates (Laguette
et al., 2014). However, the cell lines used for these studies do
not require Vpr for infection. Primary MDMs require Vpr for
optimal spread, but the mechanism by which Vpr facilitates
HIV-1 infection of macrophages has not yet been determined.
We characterized the molecular mechanism by which Vpr en-
hances HIV-1 infection in primary macrophages using three
distinct HIV-1 molecular clones. In contrast to what is observed
with Vpx-dependent SIV infection of immature monocytes, we
found no effect of Vpr on the first round of infection. However,
we noted a striking effect of Vpr on virions produced by infected
MDMs, and we noted higher infection rates in subsequent
rounds, particularly at low multiplicity of infection (MOI). Surpris-
ingly, Vpr was needed for maximal virion production only when
the HIV envelope protein (Env), which is incorporated into virions,
was also expressed. Morevover, HIV-1-infected primary MDMs
lacking Vpr had markedly reduced amounts of HIV-1 Env protein
due to increased lysosomal degradation. MDM-293T hetero-
karyons similarly restricted Env expression and virion production
demonstrating the presence of a dominant restriction in macro-
phages that can act in trans. Based on studies using Vpr mutantsevier Inc.
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this macrophage restriction. MDMs lacking Vpr produced more
IFN RNA upon initial infection, and exogenous IFNa dramatically
reduced Env expression and virion production. Thus, innate im-
mune evasion promoted by Vpr impacts HIV-1 spread in macro-
phages by preventing the activity of a macrophage-specific
intrinsic antiviral pathway that targets HIV-1 Env and that inter-
feres with the release of Env-containing virions.
RESULTS
Vpr Is Required for Optimal Spread of HIV-1 in
Macrophage Cultures at Low MOI
To explore the mechanism through which Vpr enhances HIV-1
infection of primary MDMs, we constructed a Vpr-null mutant
of the 89.6 molecular clone (89.6vpr), which was isolated
from the blood of an HIV-1-infected person with AIDS (Collman
et al., 1992). As expected based on prior published studies,
89.6vpr was not defective in permissive cell lines. Virion pro-
duction in 293T cells transfectedwith p89.6 or p89.6vpr proviral
DNA plasmids was equivalent over a range of DNA inputs (Fig-
ure S1A available online). Additionally, equal mass amounts of
89.6 and 89.6vpr virus stocks were equally infectious in
CEMx174 cells (Figure S1B) as described previously (Balliet
et al., 1994). Finally, HIV-1 89.6 and 89.6vprwere similarly infec-
tious in primary CD4+ T cells (Figure S1C, left).
In contrast, we noted striking differences in virion production
by MDMs infected with the same viral stocks of wild-type and
mutant viruses, particularly at low inoculum (Figure S1D). The
impact of Vpr on virus production was most pronounced when
the virus was allowed to spread through the culture for 18 days
(up to 20-fold differences; Figure S1C, right three panels). Thus,
89.6vpr is defective in infection of primary human MDMs, but
behaves like wild-type virus in permissive cells such as
CEMx174 and 293T cells. These results are similar to those re-
ported by others and confirm that 89.6vpr behaves as expected
(Chen et al., 2004; Connor et al., 1995; Eckstein et al., 2001).
Mechanism of Vpr-Dependent Enhancement of
MDM Infection
To determine whether the effect of Vpr we observed on the level
of virus measured in the supernatant of infected MDMs resulted
from a higher number of initially infected cells or from enhanced
spread, we validated an intracellular HIV-1 Gag staining protocol
to ensure thatwe couldmeasure true infection events, rather than
cell surface binding or endocytosis of viral particles by MDMs
(Figure 1A). At 5 days postinfection (dpi), intracellular Gag stain-
ing and flow cytometry revealed a distinct population of cells that
expressed HIV-1 Gag in a manner that was completely inhibited
byHIV-1 reverse transcription and integration inhibitors azidothy-
midine (AZT) and raltegravir, respectively (Figure 1A). Thus, we
concluded that this assay detected de novo infection of MDMs
that was dependent on reverse transcription and integration.
At the earliest time points at which we could detect intracel-
lular Gag (2 dpi), MDMs infected with an equal viral inoculum
were equally infected plus orminus Vpr (Figure 1B, left). However
by 4 dpi, we observed a higher frequency of infected MDMs with
Vpr-containing viruses (2.8-fold, p < 0.05; Figure 1B, right).
These results were confirmed using a PCR assay that detectsCell Host &HIV-1 DNA (Figures 1C and S2A); Vpr did not stimulate the
amount of cell-associated provirus detected at 2 dpi, but by 4
dpi, we detected 3- to 4-fold more provirus in Vpr-expressing
HIV-infected MDMs (Figures 1C and S2A).
In MDMs, reverse transcription and integration typically
require 2–3 days for completion of the first roundof infection (Spi-
vak et al., 2011). Thus, at 4–5 dpi, the first round of replication has
been completed, and the second round of infection has begun.
Therefore, to distinguish initial infection from spread,we inhibited
subsequent rounds of infection by the addition of raltegravir to a
subset ofMDMsat 2 dpi.We then harvested all the cells on day 4.
In the absence of raltegravir, we again observed a 2.6-fold in-
crease in the frequency of infected cells with Vpr-containing vi-
ruses (Figure 1D). However, in a side-by-side experiment using
cells from the same donor, the addition of raltegravir abrogated
this difference (Figure 1D). Thus, under the conditions of our
assay, Vpr did not affect the initial infection of MDMs and primar-
ily acted by stimulating spread of virus to new target cells.
Vpr Facilitates Spread in Macrophages by Increasing
Virion Production
To better understand how Vpr promotes spreading infection of
MDM cultures, we sought to distinguish effects of Vpr on
different HIV-1 replication stages. We hypothesized that under
conditions in which Vpr does not increase infection in the first
round of HIV-1 replication (Figure 1D), it may affect the number
of virions produced per infected cell. To examine this, we
blocked spread of HIV-1 at 2 dpi using a concentration of ralte-
gravir sufficient to fully inhibit new HIV-1 infection events and
measured virion production under these conditions (Figures 1A
and 1D). We found that Vpr increased virion production by
MDMs infected with a Vpr-containing virus an average of 5-
fold compared to HIV-1-infected MDMs lacking Vpr, which
was statistically significant across multiple donors (Figure 2A).
Of note, there were no significant differences in infected cell
number that could explain these large differences in virion pro-
duction (Figures 2B and S3A–S3E).
We also observed dramatic effects of Vpr on virion production
in MDM cultures in which HIV-1 was allowed to spread to satura-
tion over 20 days, equalizing the infection rates based on flow cy-
tometry (Figures 2C and 2D) and Gag DNA (Figures 2E and S2B).
Under these conditions of equivalent infection, Vpr increased
virion production an average of 5-fold (p < 0.01; Figure 2F).
Similar results were observed when MDMs were infected with
a T cell-tropic HIV-1 pseudotyped with amacrophage-tropic Env
(NL4-3 pseudotyped with YU-2 Env). This virus is active for a sin-
gle round of infection, but cannot spread inMDMcultures. Again,
we observed that Vpr did not significantly modulate the number
of infected MDMs (Figure S4A), but significantly increased the
number of virions releasedbyMDMs infectedwithwild-type virus
(Figures S4B and 2G). The more modest phenotype observed in
the single-round system is likely due to the use of a higher inoc-
ulum,which results in a reduced requirement for Vpr (FigureS1D),
or to other differences between the NL4-3 and 89.6 viruses.
Vpr Counteracts MDM-Specific Interference with
Release of Env-Containing Virions
Importantly, using the single-cycle infection system described
above, we noted that Vpr did not alter the release of virionsMicrobe 16, 722–735, December 10, 2014 ª2014 Elsevier Inc. 723
Figure 1. Vpr Does Not Increase the First Round of Infection in Primary Human MDM Cultures
(A) Flow cytometric analysis detecting bona fide infection ofMDMs by intracellular HIV-1Gag p24 stain. Cells were infected for 5 days with 50 mg of HIV-1 89.6 and
treated with 20 mM azidothymidine (AZT) or 2 mM raltegravir where indicated.
(B) Summary graph showing the fold difference in infection frequency observed in MDMs treated with 1 mg of wild-type or Vpr mutant virus. By definition, the
mutant virus normalizes to 1.0.
(C) qPCR analysis of gag DNA in MDMs infected with the indicated viruses. Levels of gag DNA were normalized for b-actin (ACTB) DNA levels to account for
differences in cell number (Figure S2A). Each bar represents the average of three replicates from the same donor. Error bars represent SEM. *p < 0.05, two-tailed
paired t test.
(D) Flow cytometric analysis of intracellular HIV-1Gag p24 expression inMDMs infectedwith 1 mg of the indicated viruses and analyzed at 4 dpi. Cells were treated
with 2 mM raltegravir at 2 dpi where indicated. See also Figures S1 and S2.
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from the integrated provirus (NL4-3-DE-EGFP, pseudotyped
with EnvYU-2) (Figure 2G). To confirm these results, we also
examined virion production by MDMs infected with 89.6 Env-
null and Env/Vpr-null mutants relative to wild-type and Vpr-null
viruses. We again found that mutation of Env eliminated any sig-
nificant effect of Vpr on virion production (Figure 2A). In contrast,
Env and Vpr did not affect the release of virions by permissive cell
lines (transfected 293T cells; Figure S1A). Because Env is incor-
porated into virions, these data support a model in which Vpr724 Cell Host & Microbe 16, 722–735, December 10, 2014 ª2014 Elscounteracts an MDM-specific factor or pathway that interferes
with the release of Env-containing virions.
Vpr Counteracts Interference with Env Expression by
HIV-Infected MDMs
Because our data strongly suggest that Vpr counters an MDM-
specific factor that targets Env-containing virons, we asked
whether MDMs also interfered with expression of cell-associ-
ated Env in the absence of Vpr. Indeed, we observed that
the amount of HIV-1 Env protein detected in MDMs was Vprevier Inc.
Figure 2. Vpr Increases Virion Production in
HIV-1-Infected Primary MDMs
(A) Summary graph of the effect of Vpr on virion
production, calculated as the fold change in virion
production by MDMs infected by wild-type 89.6
relative to 89.6vpr. Virion production was
normalized for the absolute number of Gag+ cells
acquired by flow cytometry within a fixed interval of
time. See also Figure S3.
(B) Summary graph of the effect of Vpr on the
number of infected cells, calculated as the fold
change in the number of MDMs infected by wild-
type 89.6 relative to 89.6vpr. Each shape in (A)
and (B) represents a replicate from one experiment
from a single donor. Error bars represent SEM.
(C) Flow cytometric analysis of HIV-1 Gag p24
expression in MDMs infected for 20 days with 1 mg
of the indicated viruses.
(D) Compilation of flow cytometry experiments
staining for intracellular HIV-1 Gag p24 in MDMs
infected as in (C).
(E) qPCR analysis of gag levels in MDMs from a
duplicate well from the experiment in (C). Levels of
gag DNA were normalized for b-actin (ACTB) DNA
levels to account for differences in cell number.
See also Figure S2.
(F) Virion production based on HIV-1 Gag p24
levels in the supernatant of MDMs from three do-
nors for which infection rates were shown in (D).
Error bars represent SEM. *p < 0.05, **p < 0.01,
two-tailed paired t test. In (D) and (F) each symbol
represents a different donor (n = 3).
(G) Summary graph of virion production by MDMs
4 days postinfection with YU-2 envelope-pseudo-
typed NL4-3 wild-type or containing the indicated
mutations. The mean ratio of viral production/
infection frequency is shown ± SD. *p < 0.01, **p <
0.001, two-tailed paired t test, n = 3 replicates from
each donor. See also Figure S4.
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(Figures 3A and 3B). The effect of Vpr on Env was MDM-specific
because we observed no significant effect of Vpr on Env expres-
sion in 293T cell lines transfected with proviral DNA (Figure S5A).
To more accurately assess the effect of Vpr on Env per infected
cell, we examined serial dilutions of whole-cell lysate (WCL) and
compared Env levels only for dilutions in which Gag pr55 expres-
sion was matched. Vpr consistently increased the expression of
the processed gp41 form of Env (4- to 5-fold; Figures 3A and 3B).
The gp160 precursor and processed gp120 forms of Env were
also affected, but to a lesser extent than gp41 (2- to 4-fold; Fig-
ures 3A and 3B). Vpr also significantly increased the amount of
processed Gag p24 in most donors (Figures 3A and 3B). How-Cell Host & Microbe 16, 722–735, Dever, this effect was more modest on
average (about 2-fold) and varied consid-
erably across donors.
To determine whether modulation of
Env expression varied over the time
course of infection, we analyzed Env ex-
pression in MDMs over time. To accu-
rately compare the level of Env, we again
performed serial dilutions and comparedsamples in which Gag pr55 expression was matched. We found
that Vpr enhanced Env gp160 and gp120 expression even at 5
dpi (Figure 3C). However, the effect of Vpr on these forms of
Env became more dramatic over time (Figure 3C). Indeed, by
20 dpi, Vpr increased Env gp160 and gp120 7- and 15-fold,
respectively (Figures S5B and S5C).
To verify that these effects of Vpr were not specific to a single
molecular clone of HIV-1, we performed similar experiments us-
ing HIV-1 molecular clone AD8 and a well-characterized AD8
Vpr-null mutant (Rey et al., 1998; Theodore et al., 1996). We
again observed no defect in Env expression by the mutant virus
in transfected 293T cells (Figure S5D). However, MDMs infected
with AD8vpr displayed substantially lower levels of Env relativeecember 10, 2014 ª2014 Elsevier Inc. 725
(legend on next page)
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As with 89.6, this effect of Vpr was especially notable for Env
gp41 where we observed an average of 7-fold more protein in
MDMs infected with wild-type virus (Figures 3D and 3E). Again,
we observed a more variable effect of Vpr on Env gp160 precur-
sor (Figures 3D and 3E). Furthermore, we also observed effects
of Vpr on NL4-3 Env when YU-2 Env-pseudotyped NL4-3 was
used to infect MDMs (Figure S4C). Thus, the ability of Vpr to in-
crease Env protein expression and virion production in MDMs
is conserved among HIV-1 variants isolated from different HIV-
1-infected people.
To determine whether the defect in cell-associated Env expres-
sion also led to diminished incorporation of Env into virions, we
lysed virus from infected MDM supernatants and analyzed it by
immunoblot. We found that Vpr significantly enhanced Env incor-
poration into virions by an average of 2- to 3-fold (Figures S5E and
S5F). However, when MDMs were infected with equal mass
amounts of MDM-derived virus containing or lacking Vpr, we
observed equal numbers of infected cells (data not shown).
Thus,MDMsexpress a factor orpathway that interfereswith incor-
poration of Env into virions and that inhibits their release, but under
the conditions of our assay, themagnitude of the interferencewas
notsufficient toalter the infectivityof the residual recoveredvirions.
Vpr Prevents Lysosomal Degradation of HIV-1
Env in MDMs
To determine the mechanism by which MDMs interfere with Env
expression, we performed a pulse-chase analysis of Env protein
synthesis and decay in infected MDMs at 10 dpi. Vpr did not
affect the quantity of the precursor form of Env (gp160) synthe-
sized within the 1 hr pulse (n = 8; Figure 4A; data not shown).
However, Vpr increased the half-life of the processed form
(gp120) from 3.3 hr to 7.7 hr (p < 0.0001; Figures 4A and 4B).
In contrast, there was no significant effect of Vpr on the half-
life of HIV-1 Gag pr55 or Gag p24 (Figure 4A; data not shown).
Based on quantitation of b-actin and HIV-1 gag DNA, the
numbers of infected cells added to the assay were similar (Fig-
ures 4C and 4D). In sum, these results indicate that Vpr increases
Env protein expression by a posttranslational mechanism that
prevents Env degradation.
To determine which degradative pathways affected Env in
MDMs infected with 89.6vpr, we treated cells that were pulse
labeled for 1 hr and chased with nonlabeled media for 8 hr with
ammonium chloride, an inhibitor of lysosomal degradation, orFigure 3. HIV-1 Vpr Increases Env Expression in MDMs
(A) Immunoblot analysis of HIV-1 protein expression in whole-cell lysates (WCLs)
and gp120 were detected with anti-gp120 antibody, gp41 was detected by anti-
MDMs infected with wild-type 89.6 were serially diluted as indicated. Arrows d
absence of vpr.
(B) Summary graph quantifying the fold increase in expression of the indicated HI
Each symbol denotes the antibody used to detect the indicated protein and repre
represent SEM. *p < 0.05, **p < 0.005, ****p < 0.00005, two-tailed paired t test.
(C) Immunoblot analysis of viral protein levels in WCLs from MDMs infected fo
transfected for 2 days with the indicated HIV-1 genomic DNA plasmids. WCLs fr
(D) Immunoblot analysis of viral protein levels in WCLs from MDMs infected for 6
wild-type AD8 were serially diluted in loading buffer as indicated.
(E) Summary graph of the effect of Vpr on expression of the indicated HIV-1 prote
1 mg of wild-type AD8 relative to AD8vpr. Each symbol denotes the antibody
performed in a different donor (n = 3). Error bars represent SEM. *p < 0.05, two-
Cell Host &MG132, an inhibitor of proteasomal degradation. Ammonium
chloride, but notMG132, partially rescued Env gp120 expression
(p < 0.002; Figures 4E and 4F). In contrast, ammonium chloride
treatment did not significantly affect Gag pr55 levels or Gag
p24 over the 8 hr time course of this assay (Figures 4E and
4G). These data demonstrate that HIV-1 Env is targeted to lyso-
somes in HIV-1-infected cells lacking Vpr.
Vpr Counteracts a Dominant Restriction of Env and
Virion Production in MDMs
To determine whether Env expression is diminished in MDMs
because of a negative restriction factor that is counteracted by
Vpr or because MDMs lack a positive cofactor that Vpr provides,
we examined Env expression and virion production in hetero-
karyons of restricted (MDM) and permissive (293T) cells. Hetero-
karyons were generated using Newcastle disease virus (NDV)
fusion proteins (F and HN) and HIV-1, which promotes cellular
fusion via Env on transfected 293T cells and CD4 on MDMs. In
these experiments, 293T cells were transfected equally by
HIV-1 89.6 and 89.6vpr, and spread of HIV-1 toMDMswas pre-
vented by the addition of raltegravir (Figures 5A and 5B). Similar
to previously publishedwork (Kaushik et al., 2009; Sharova et al.,
2008) we observed that NDV fusion proteins and HIV-1
enhanced the fusion of transfected 293T cells to uninfected
MDMs, and fewer than 10% of 293T cells were unfused at the
time of harvest (Figure 5C). Remarkably, we found that MDM-
293T heterokaryons restricted Env expression and virion pro-
duction, whereas 293T homokaryons did not (Figures 5D and
5E). Moreover, the heterokaryon-specific restriction was coun-
teracted by Vpr (Figures 5D and 5E). Collectively, our data indi-
cate that Vpr counteracts a macrophage-specific restriction
factor that targets Env for lysosomal degradation and impairs
the release of virions.
DCAF1 Is Required for Vpr to Counteract Restriction of
Env Expression and Virion Production in MDMs
Studies performed in permissive cells have shown that HIV-1 Vpr
interacts with a cellular ubiquitin ligase complex through the
adaptor protein DCAF1. Because lentiviral accessory proteins
commonly utilize ubiquitin ligase substrate adaptors to target re-
striction factors for degradation, we examined whether DCAF1 is
required for Vpr to overcome the restriction we observed in
MDMs. Interestingly, we observed that a mutant Vpr (VprQ65R)
that is defective at DCAF1 interactions, DCAF1-dependent cellfrom MDMs infected for 10 days with 1 mg of the indicated viruses. Env gp160
gp41 antibody, and Gag pr55 and p24 were detected with HIV-Ig. WCLs from
enote samples containing comparable levels of Gag pr55 in the presence or
V-1 proteins in MDMs infected with wild-type 89.6 relative to 89.6vpr as in (A).
sents a separate experiment performed in a different donor (n = 19). Error bars
r the times indicated with 1 mg of the indicated viruses and from 293T cells
om MDMs infected with wild-type 89.6 were serially diluted as indicated.
days with 1 mg of wild-type AD8 or AD8vpr. Lysates from MDMs infected by
ins, calculated as fold change in protein levels in MDMs infected for 6 days with
used to detect the indicated protein and represents a separate experiment
tailed paired t test. See also Figures S4C and S5.
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Figure 4. Vpr Prevents Lysosomal Degrada-
tion of Env in Primary Human MDMs
(A) Radioimmunoprecipitation assay of HIV-1
proteins from primary human MDMs infected with
1 mg of wild-type 89.6, cultured for 10 days prior,
and metabolically labeled with [35S]Met/Cys for
1 hr. The labeled cells were chased for the indi-
cated time periods, immunoprecipitated, and
subjected to SDS-PAGE.
(B) Summary of quantified data from the experi-
ments performed as in (A). The fraction of gp120
remaining at 8 hr or 16 hr relative to T0 was
calculated as described in Supplemental Experi-
mental Procedures. Each dot represents a
different donor from a separate experiment (n = 3).
Best-fit curves were obtained by nonlinear
regression analysis.
(C and D) qPCR analysis of gag (C) and b-actin (D)
DNA levels in cells analyzed in (B). Cells were
treated with 10 mg/ml AMD3100 and 20 mM mar-
aviroc or 2 mM raltegravir during infection where
indicated. Each shape represents a different
donor from a separate experiment (n = 3).
(E) Radioimmunoprecipitation assay of HIV-1
proteins from primary human MDMs infected and
radiolabeled as described for (A). As indicated,
labeled cells were chased for 8 hr with or without
inhibitors of lysosomal and proteasomal degra-
dation (20 mM NH4Cl and 2.5 mM MG132,
respectively).
(F and G) Quantification of Env gp120 (F) and Gag
pr55 (G) levels in cells treated as in (E). Env
expression was calculated as the fold change in
proteinmeasured inWCLs fromMDMs infected by
89.6vpr relative to wild-type 89.6. Each shape
represents a different donor from a separate
experiment (n = 3). Error bars represent SEM. *p <
0.05, two-tailed paired t test.
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Hrecka et al., 2007; Laguette et al., 2014) was similarly defective
at enhancing Env expression and virion production (Figure S6).
To more directly demonstrate a causal relationship between
DCAF1-Vpr interaction and Vpr-mediated increases in virion
production and Env expression, we silenced DCAF1 expression
in primary human MDMs. To accomplish this, we used an
shRNA-expressing lentiviral construct that had been optimized
to maximize silencing while limiting antiviral responses in
MDMs (Pertel et al., 2011). Using this system we reproducibly
achieved efficient silencing of DCAF1 expression (Figure 6A).
Remarkably, we observed that DCAF1 silencing dramatically
reduced Env expression (Figure 6B) and virion production (Fig-
ure 6C) in wild-type HIV-1-infected MDMs. Indeed, without
DCAF1 expression, Env expression was similar between wild-
type and Vpr-null viruses (Figure 6B). Thus, these studies indi-
cate that Vpr requires interaction with the DCAF1-DDB1-CUL4
E3 ubiquitin ligase to overcome restriction of virion production
and Env expression in HIV-1-infected MDMs.728 Cell Host & Microbe 16, 722–735, December 10, 2014 ª2014 Elsevier Inc.Vpr Disrupts a Pathway that Leads
to Induction of Type I IFN
Recent studies have shown that induc-
ible Vpr expression in a HeLa cell line ac-tivates the SSE regulator SLX4 complex (Laguette et al., 2014).
In this cell-line system, induction of Vpr increases polo-like ki-
nase-1 (PLK-1) levels and stimulates the ubiquitylation and turn-
over of MUS81-EME1 endonucleases (Laguette et al., 2014) in a
manner that requires the DCAF1-DDB1-CUL4 E3 ubiquitin
ligase complex. We demonstrate here that this pathway is intact
in primary human MDMs and CD4+ lymphocytes (Figures S7A
and S7B). Compared to infected cells lacking Vpr, wild-type
HIV-1 infection led to the accumulation of PLK-1 and increased
the turnover of MUS81 and DCAF1 in primary MDMs (Fig-
ure S7A). In primary CD4+ T cells, we additionally noted
decreased amounts of the Vpr-interacting protein uracil-DNA
glycosylase 2 (UNG2) as previously reported (Priet et al.,
2003; Wen et al., 2012). In MDMs, the levels of UNG2 were
not assayable due to lower expression levels (data not shown).
Interestingly, DCAF1 was diminished as early as 5 hr postinfec-
tion (hpi) in MDMs, consistent with its utilization by Vpr (Fig-
ure S7C). Vpr-dependent downmodulation of DCAF1 at 5 hpi
was completely reversed by the addition of the proteasome
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Figure 5. Vpr Counteracts a Dominant Restriction of Env and Virion Production in MDMs
(A) Outline of experimental setup in which 293T cells transfected with HIV-1 and paramyxovirus fusion proteins were fusedwith uninfectedMDMs for 4 days in the
presence of raltegravir to prevent viral spread to unfused MDMs.
(B) Flow cytometric analysis of intracellular Gag expression by 293T at 2 days posttransfection with the indicated HIV expression plasmid.
(C) Flow cytometric analysis of 293T cells that were mock transfected (unfused) or transfected with paramyxovirus fusion proteins and the indicated HIV plasmids
(fused), stained with DiO, and cultured as indicated with DiD-stainedMDMs in the presence of raltegravir. Numbers represent frequency of residual unfused 293T
cells.
(D) Immunoblot of 293T cell homokaryons and MDM+293T heterokaryons. Env gp41 quantitation reflects densitometrically determined values relative to Gag
pr55.
(E) Virion production by 293T cell homokaryons and MDM-293T heterokaryons measured and calculated as described in Figure S3 and normalized to wild-type.
Error bars represent SEM.
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HIV-1 Vpr Counteracts a Restriction Targeting Envinhibitor MG132 (Figure S7C), indicating that virion-associated
Vpr utilizes DCAF1 at very early time points prior to the estab-
lishment of productive infection.
Because activation of the DCAF1-SLX4 pathway diminishes
viral sensing and limits type I IFN responses in HeLa cells (Lagu-Cell Host &ette et al., 2014), we examined IFN responses in infected
MDMs. Remarkably, we found that wild-type HIV-1-infected
MDMs exhibited lower IFNA1 gene expression compared to
Vpr-null-infected MDMs at 12 hpi (Figure 7A). Furthermore, the
magnitude of the difference in IFNA1 response correlated withMicrobe 16, 722–735, December 10, 2014 ª2014 Elsevier Inc. 729
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MDMs transduced with lentiviral vectors ex-
pressing shRNAs targeting DCAF1 or luciferase
(Control) and incubated for 7 days (first 3 days with
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transduction.
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Quantitation reflects densitometric analysis of Env
gp41 expression normalized for Gag pr55
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represent SEM. See also Figure S6.
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HIV-1 Vpr Counteracts a Restriction Targeting Envthe degree to which Vpr enhanced virion production at 10 dpi
(Figure 7B).
To directly assess whether type I IFN may contribute to re-
striction of Env and virion production in MDMs, we treated
infected MDMs with IFNa at 7 dpi and harvested at 10 dpi
(Figure 7C). Because we observed that IFNa completely in-
hibited new infections when added at day 0, we added ralte-
gravir to established infections at the time of IFNa addition
to eliminate confounding effects due to differences in spread.730 Cell Host & Microbe 16, 722–735, December 10, 2014 ª2014 Elsevier Inc.Under these conditions, we observed
that IFNa treatment strikingly reduced
HIV-1 Env gp41, gp120, and gp160 pro-
tein levels relative to Gag pr55 in multiple
donors (Figure 7D). Additionally, IFNa
treatment suppressed virion production
per infected cell (Figure 7E). These data
support a model in which Vpr facilitates
Env expression and release of Env-con-
taining virions by limiting induction of
IFNa production upon HIV-1 infection of
MDMs.
DISCUSSION
Vpr is an HIV-1 accessory protein and
virulence factor associated with high viral
loads and progression to AIDS (Lang
et al., 1993; Somasundaran et al., 2002).
In vitro, Vpr promotes HIV-1 infection of
restricted primary cells such as macro-
phages (Le Rouzic and Benichou, 2005).
However, the mechanism by which Vpr
facilitates infection is poorly understood.
In agreement with other studies, we
observed that Vpr enhances viral infec-
tion and spread in macrophages (Chen
et al., 2004; Connor et al., 1995; Eckstein
et al., 2001). Here we demonstrate that
Vpr enhanced spread by increasing the
number of virions released per infectedcell when HIV-1 Env was also expressed. In addition, all Vprs
tested (89.6, NL4-3, and AD8) dramatically increased the expres-
sion of HIV-1 Env, a necessary component of HIV-1 virions that
binds to the CD4 receptor and coreceptors (Freed and Martin,
1995) to facilitate viral fusion to target cells. Env is also necessary
for formation of the virological synapse, which is required for
cell-to-cell spread (Jolly et al., 2004). Therefore, it is likely that
Vpr-dependent increases in Env expression also enhance
cell-to-cell spread by facilitating virological synapse formation.
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Figure 7. Vpr Counteracts an Antiviral Inter-
feron Response in MDMs that Restricts Env
and Virion Production
(A) IFNA1 gene induction in MDMs infected for
12 hr with 100 mg of wild-type 89.6 or 89.6vpr as
measured by qRT-PCR, normalized to ACTB, and
expressed as fold induction relative to mock and
normalized to Vpr null (n = 3 donors).
(B) Graphical analysis demonstrating an inverse
correlation between IFNA1 gene induction as
measured in (A) and Vpr stimulation of virion pro-
duction at 10 days postinfection with 1 mg of each
virus. Best-fit curve and R2 value were obtained by
linear regression analysis (n = 3 donors).
(C–E) (C) Outline of experimental setup for MDMs
treated with 500 U/mL recombinant human IFNa
and assessed for Env expression (D) and virion
production (E) in two independent experiments.
Error bars represent SEM. *p < 0.05, two-tailed
paired t test. See also Figure S7.
Cell Host & Microbe
HIV-1 Vpr Counteracts a Restriction Targeting EnvIndeed, we observed a greater effect of Vpr when HIV-1 was
allowed to spread through the MDM culture.
The results presented herein demonstrate that macrophages
express a cell type-specific restriction factor that targets newly
made Env protein and Env-containing virions. This determina-
tion is strongly supported by several key observations: (1) Vpr
enhanced virion production only when Env was expressed
(null mutations in 89.6 and NL4-3 env eliminated the ability of
Vpr to stimulate virion production), (2) Vpr stimulated Env
expression and Env-containing virion production in restricted
cells (macrophages), but not in permissive cell lines (293T),
(3) permissive cells acquired the capacity to restrict EnvCell Host & Microbe 16, 722–735, Dexpression and release of Env-contain-
ing viral particles when fused to
restricted cells (primary macrophages),
indicating that macrophages harbor a
dominant restriction factor that can act
in trans, and (4) Vpr counteracts the
restriction in macrophages and in 293T-
macrophage heterokaryons. In sum,
these data demonstrate that in the ab-
sence of Vpr, a dominant factor restricts
the expression of Env protein and the
release of Env-containing virions in mac-
rophages. Moreover, Vpr functions to
counteract this restriction.
While our data clearly demonstrate that
restriction of cell-associated Env occurs
via accelerated lysosomal degradation
in MDMs lacking Vpr, additional studies
are needed to understand the fate of
Env-containing virions in these cells.
Prior studies have shown that cellular
proteins that bind Env can also reduce
release of Env-containing virions (Ross
et al., 1999; Lama et al.,1999). Thus,
Vpr could enhance virion release by
counteracting an MDM-specific factor
that binds Env on budding virions,reducing virion release. Based on pulse-chase analysis of cell-
associated p24 summarized herein, Vpr did not detectably
affect virion assembly, budding, retention, and degradation up
to 16 hr postsynthesis. However, if MDMs both retain and
degrade virions in the absence of Vpr, virion retention could
mask virion degradation at early time points. Based on western
blot analysis, which provides an assessment of steady state
cell-associated p24 averaged over longer time periods, it ap-
pears that cell-associated virions are eventually degraded in
the absence of Vpr. However, more studies are needed to
conclusively determine what happens to virions in HIV-1-in-
fected MDMs lacking Vpr.ecember 10, 2014 ª2014 Elsevier Inc. 731
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HIV-1 Vpr Counteracts a Restriction Targeting EnvWe also found that virions released by MDMs lacking Vpr had,
on average, 2- to 3-fold less Env, confirming our observations
that Env is targeted by an MDM-specific factor that is counter-
acted by Vpr. Interestingly, CD4 expression also interferes with
Env incorporation into virions produced by transfected 293 cells
that lack Nef. Nef expression counteracts this interference and
promotes Env incorporation into virions (Lama et al., 1999).
The interference mediated by CD4 appears to be analogous to
the MDM-specific restriction we describe herein, which is coun-
teracted by Vpr.
Previously identified Vpr-dependent phenotypes observed in
permissive cell-line systems depend on an interaction with the
Cul4A-DDB1-DCAF1 ubiquitin ligase (Ahn et al., 2010; Belzile
et al., 2007; Hrecka et al., 2011; Le Rouzic et al., 2007; Wen
et al., 2007), which activates the SLX4-endonuclease complex.
Vpr- andDCAF1-dependent activation of the SLX4 endonuclease
complexmay suppress accumulation of unprocessedHIV-1 DNA
intermediates that otherwise induce IFNa and IFNb (Laguette
et al., 2014). Thus, the macrophage-specific restriction we
describe may result from cellular detection of viral infection and
activation of an innate immune response. Several lines of evi-
dence presented herein support this model: (1) the Vpr-depen-
dent SLX4 pathway that suppresses innate immune detection
of viral infection was active in primary macrophages, (2) DCAF1,
a cellular cofactor required for Vpr to activate the SLX4 complex
was also required for Vpr-dependent stabilization of Env and effi-
cient release of Env-containing virions in macrophages, (3) Vpr
significantly reduced IFNa induction in macrophages from three
donors at early time points, (4) the magnitude of IFNa induction
observed in donor macrophages correlated with the magnitude
of the Vpr-dependent virion production phenotype detected in
macrophages from the same donor at later time points, and (5)
addition of IFNadramatically reducedEnv expression and release
of virions even in infected macrophage cultures that expressed
Vpr. Thus, these data support a model in which Vpr functions to
prevent innate immune recognition of infection, IFN induction,
and the activation of downstream pathways that disrupt Env pro-
tein expression and virion release. Whether SLX4 is directly
required for IFN modulation and whether low amounts of type I
IFN induced at the time of initial infection are sufficient for the
macrophage restriction will require further experimentation.
Importantly, our results provide strong and convincing evi-
dence that the Vpr-DCAF1 complex is linked to a virological
endpoint in a restricted cell type. The observation that Vpr affects
a late process in the viral life cycle was initially surprising,
because the efficient incorporation of Vpr into virions suggests
it acts on a step in the viral life cycle preceding integration (Lu
et al., 1995). Indeed, we report here that Vpr causes accelerated
turnover of DCAF1 via a proteasomal mechanism as early as
5 hpi and prior to the establishment of productive infection.
Thus, Vpr packaged into virions is sufficient to initiate DCAF1-
dependent pathways. Interestingly, the proteasome inhibitor,
MG132, blocked Vpr-induced early turnover of DCAF1, but did
not affect macrophage restriction of Env expression that
occurred later, after infection was established. This observation
suggests that at least a component of Vpr’s capacity to rescue
Env expression resulted from an indirect, downstream effect of
DCAF1 and Vpr. Whether viral sensing that occurs in the
absence of Vpr results in the upregulation of a cellular factor732 Cell Host & Microbe 16, 722–735, December 10, 2014 ª2014 Elsthat binds and disrupts Env and Env-containing virions is an
interesting possibility that remains to be investigated.
In addition to DCAF1, Vpr also accelerates the turnover of
cellular cofactors MUS81, the endonuclease contained within
the SLX4 complex that is activated by Vpr to possibly degrade
HIV-1 replication intermediates and limit induction of the innate
immune response (Laguette et al., 2014), and UNG2, a uracil gly-
cosylase (Priet et al., 2003;Wen et al., 2012). Interestingly, UNG2
may reduce the accumulation of uracilated DNA intermediates in
HIV-1-infected primary CD4+ T cells expressing Vpr (Norman
et al., 2011). Whether UNG2 and the SLX4 complex work coop-
eratively to clear HIV-1 intermediates and prevent immune acti-
vation in HIV-1-infected primary cell systems is an interesting
hypothesis that remains to be investigated.
In summary, we have determined that Vpr increases spread of
HIV-1 in MDMs by counteracting an MDM-specific restriction of
Env expression that leads to lysosomal degradation of Env and
impaired release of Env-containing virions. Notably, this pathway
relies upon the expression of the Vpr cofactor DCAF1, and this
interaction is necessary for optimal infection ofMDMs, a restricted
primary cell type.Macrophages represent an important conduit for
HIV-1 infection of CD4+ T cells and are infected during the acute
phase of HIV-1 infection (Hladik et al., 2007). Thus, these studies
provide important insights into how HIV-1 evades the innate im-
mune pathways that would otherwise recognize and restrict viral
infection in primary cells that are the targets of HIV-1 in vivo.
EXPERIMENTAL PROCEDURES
Antibodies, cell lines, and viral constructs are described in Supplemental
Experimental Procedures.
Cell Culture and Viral Infection
Leukocytes isolated from anonymous donors by apheresis were obtained from
New York Blood Center Component Laboratory (Long Island City). Peripheral
bloodmononuclear cells (PBMCs) were purified by Ficoll density gradient sep-
aration as described (Norman et al., 2011). CEMx174 cells were cultured in
R10 and infected with HIV-1 by spinoculation as described in Supplemental
Experimental Procedures (Salter et al., 1985).
CD14+monocytes were isolated by positive selection with an EasySepmag-
netic sorting kit (STEMCELL Technologies). MDMs were obtained by culturing
monocytes in R10 (RPMI-1640 with 10% fetal bovine serum [Gibco, Invitro-
gen], penicillin [10 U/ml], streptomycin [10 mg/ml], L-glutamine [292 mg/ml],
M-CSF [50 ng/ml, R&D Systems], and GM-CSF [50 ng/ml, R&D Systems])
for 7–9 days, as described (Lahouassa et al., 2012). MDMs were incubated
with HIV-1 for 4 hr, washed with PBS, and cultured in fresh medium, as
described (Peeters and Courgnaud, 2002). For IFNa treatment experiments,
cells were treated with 500 U/ml recombinant human IFNa (Calbiochem) as
described in Figure 7.
Flow Cytometric Analysis
Intracellular staining for Gag CAp24 expression was performed as described
previously (Carter et al., 2010).
Western Blotting
MDM WCL Preparation
MDMs infected with HIV-1 were washed with PBS before being lysed in Blue
Loading Buffer (Cell Signaling Technology). WCLs were sonicated with aMiso-
nix Sonicator (QSonica) and clarified by centrifugation at 13,000 rpm.
Viral Lysate Preparation
Supernatant from infected cells was passed through a 0.45 mm filter, and vi-
rions were pelleted by ultracentrifugation at 25,000 rpm, as described (McCall
et al., 2008). The virus-containing pellet was lysed in Blue Loading Buffer and
clarified by centrifugation at 13,000 rpm.evier Inc.
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HIV-1 Vpr Counteracts a Restriction Targeting EnvLysates were analyzed by immunoblot, and protein levels were quantified
using Adobe Photoshop as described (Norman et al., 2011).
Virion Quantitation
Supernatant containing viral particles was lysed in Triton X lysis buffer
(0.05% Tween 20, 0.5% Triton X-100, 0.5% casein in PBS). Antibody to
HIV-1 CAp24 antibody (clone 183-H12-5C) was bound to Nunc MaxiSorp
plates. Lysed samples were captured for 1–2 hr and incubated with bio-
tinylated antibody to HIV-1CAp24 (clone 31-90-25). 31-90-25 was bio-
tinylated with the EZ-Link Micro Sulfo-NHS-Biotinylation Kit (Pierce).
Samples were detected using streptavidin-HRP (Fitzgerald) and 3,30,5,50-
tetramethylbenzidine substrate, as described (Salmon and Trono, 2007).
CAp24 concentrations were measured by comparison to recombinant HIV-
1 CAp24 standards (ViroGen). Virion production was normalized for infected
cell number by dividing the CAp24 measured by ELISA in supernatant by the
number of Gag+ cells acquired by flow cytometry within a fixed interval of
time.
Preparation of CD4+ Lymphocytes
CD4+ lymphocytes were prepared as follows: adherence-depleted PBMCs
were depleted of CD56+ cells (EasySep, STEMCELL Technologies) and
CD8+ cells (Dynabeads, Sigma) by negative selection. CD4+ lymphocytes
were stimulated in R10 and phytohaemagglutinin (PHA; 5 mg/ml). IL-2 (500
IU/ml) was added to the culture 24 hr following PHA stimulation. CD4+
T cells were infected with HIV-1 by spinoculation (2,500 rpm at 25C for 2–
3 hr) 48–72 hr following PHA stimulation, as described (Norman et al., 2011).
Infected cells were maintained in R10 and IL-2 until analyzed.
Quantitative PCR
DNA was isolated from 4 to 5 3 105 MDMs using the DNeasy Blood & Tissue
Kit (Qiagen). HIV-1 DNA and ACTB DNA were quantified by quantitative PCR
(qPCR) using specific primers as described previously (Clouse et al., 1989;
McNamara et al., 2013; Norman et al., 2011). Dilutions of ACH-2 DNA (Clouse
et al., 1989; Folks et al., 1989) were used to calculate gag copy number and
relative DNA input.
Quantitative RT-PCR
RNA was isolated from MDMs using RNeasy Kit (Qiagen) with on-column
DNase I digestion. RNA was reverse transcribed using AffinityScript qPCR
cDNA Synthesis Kit (Agilent Technologies) with 8.5 ng/ml oligo dT and
1.5 ng/ml random nonamers. cDNA was amplified with QuantiTect SYBR
Green PCR Kit (Qiagen) on an Applied Biosystems 7300 Real-Time PCR
System using commercially available IFNA1 primers (Prime PCR,
qHsaCED0020782, Bio-Rad) or with TaqMan Gene Expression Master Mix
with b-actin primers and FAM-MGB probes (TaqMan Gene Expression,
Hs99999903_m1, Life Technologies) (Applied Biosystems). Reactions were
quantified using ABI Sequence Detection software compared to serial dilu-
tions of a single-stranded DNA oligo spanning the IFNA1 amplicon, or cDNA
frommock-treated cells. Calculated copies from the no-RT controls were sub-
tracted from the calculated copies of the cDNA samples, then normalized for
input measured by b-actin.
Radioimmunoprecipitation Assay
Metabolic labeling of HIV-1-infected MDMs was performed as described (Ono
and Freed, 1999). For additional details, see Supplemental Experimental
Procedures.
RNA Interference
Short hairpin RNA-mediated silencing of DCAF1 was performed as previously
described (Pertel et al., 2011). Briefly, we spinoculated primary monocytes
with VSV-G-pseudotyped SIV3+ for 2 hr with 10 mg/ml polybrene to allow
Vpx-dependent downmodulation of SAMHD1. Cells were then incubated
overnight in RPMI+10% certified endotoxin-low FBS (Invitrogen) with M-CSF
(50 ng/ml, R&D Systems) and GM-CSF (50 ng/ml, R&D Systems) plus 20 mg
VSV-G-pseudotyped lentivirus containing an shRNA cassette targeting lucif-
erase (control) or DCAF1. Following an overnight incubation, the cells were
cultured for 3 days in fresh medium before addition of 10 mg/ml puromycin
for 3 additional days prior to infection.Cell Host &Generation of 293T-MDM Heterokaryons
293T cells transfected with p89.6 or p89.6vpr and paramyxovirus fusion pro-
tein expression plasmids (pCAGGS-NDV-HN and pCAGGS-NDV-F, Dr. Trudy
Morrison, University of Massachusetts Medical School; McGinnes and Morri-
son, 2006) were stained with Vybrant DiO (Invitrogen). Uninfected MDMs
prepared as described above were stained with Vybrant DiD (Invitrogen).
Transfected 293T cells were cultured alone or with MDMs (3:1, 293T:MDM)
for 4 days in media containing 2 mM raltegravir and were trypsinized prior to
harvest.
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